Algernon Health Inc (AGNPF)

[Money $hot]

The operative word is "Compensation". Management believes it's earned its keep on this (merry) go-down.

96000 Options represents 4.5% of the overall diluted Common Shares, Warrants, Agent Warrant Units, Stock Options = 2,130,470 Full Diluted Shares.

96,000 stock options exercisable at $4.10 for five years from date of grant = One tenth (1/10th) of the 52 Week High of $41.00 CAD

A 90% Discount.

^That's the insane part of management compensating itself by any rationale it chooses.

I for one do not see how they have earned it by any stretch of the imagination, but hey it's a new year and nothing will surprise me when it comes to management looking out for themselves 1st and foremost.

Lesson Learned the overwhelmingly hard way.

Things that would warrant any options passed around like candy at rock bottom prices is a Nasdaq Listing (while each of us still has vital signs), a Grant(s) to help fund clinical trial(s), a partnership to fund clinical trials, no more toxic financing with family and friends and Cayman Islands and/or any deal that includes toxic warrants and Smackie Mackie and Andre Uddin (Mackie's insider anal-yst).

Nasdaq/Grants/Partnerships/Abolishing Toxic Financing

Addressing any of those issues and management will be doing something it has yet to accomplish.

Thus far, we can only rely on the past practices of management and that's a primary reason the market remains highly skeptical of Christopher Moreau's public plea to shareholders that the best is yet to come.

When, How?

Christopher Moreau has stuck his neck out in a major way with his latest interview with Streetwise Reports.

Christopher Moreau laid the blame of Algernon's abysmal market cap at the feet of his home countrymen.

That's the type of shit you better be able to back up once it rolls out of your mouth with forethought.

Christopher Moreau has publicly pleaded to shareholders' faces on Biopub webcast, in corporate news releases, and the Streetwise Reports interview that Algernon Pharmaceuticals must uplist.

Thus, time is not on our side as Algernon moves forward with it's agenda and in need of financing at some point.

Will they run the same plays as always?

I must say i lack confidence in Christopher Moreau’s Streetwise Reports interview when he stated:

He said it “may take some time, but I believe we will slowly get to the valuation we deserve for all of our research programs” on the Nasdaq.

The company said there is no timeline for when its Nasdaq application could be approved, but a guide on the Nasdaq website said it usually takes four to six weeks for an initial application to be considered.

Christopher Moreau can do a lot of damage (Drunken Monkey Fire Sale Dilution) to shareholders with a "take some time" strategy moving forward.

It has never taken management any time to drive the bus over a cliff every year since 2018.

I'd hope for once Christopher Moreau has something in the wings that actually excites the market.

Something that can register as a truly positive Catalyst.

One hopes Nasdaq will take control of the narrative to the point Moreau can just shut his mouth and let the market run the story.

We've had enough of the half baked half-ass messaging that only moves the yellow bus gas needle towards an empty tank - at full throttle - headed over the cliff.

Get your pilot license Christopher Moreau.

Driving the yellow bus bus has proven time and again to be deadly for all (dead stock).

M$

Outro